RECORDATI REPORTS SIGNIFICANT GROWTH IN THE FIRST NINE MONTHS 2013

• Consolidated revenue € 702.0 million, + 13.2%. 

• EBITDA⁽¹⁾ € 174.0 million, + 15.4% 

Operating income € 148.3 million, + 12.0%. 

Net income € 101.5 million, + 9.0%. 

Net financial position⁽²⁾:  net debt of € 133.3 million. 

Closing of the acquisition of a portfolio of drugs for the treatment of rare and other diseases in the U.S.A.. 

Agreements signed for the acquisition of Opalia Pharma S.A., a Tunisian pharmaceutical company. 

Acquisition of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company. Transaction closed in October. 

Full year 2013 targets updated. 

Interim 2013 dividend of € 0.22 per share to be distributed. 

Milan, 30 October 2013 - The Board of Directors of Recordati S.p.A. approved the Group's consolidated results for the first nine months 2013 prepared in accordance with International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) and in particular as per IAS 34 requirements for interim reporting. These financial statements will be available today at the company's offices and on the company's website:
http://www.recordati.com/rec_en/investors/reports/ and can also be viewed on the website of Borsa Italiana S.p.A.

Financial highlights

• Consolidated revenue in the first nine months 2013 is € 702.0 million, up by 13.2% compared to the same period of the preceding year. International sales grow by 16.5%. 

• EBITDA⁽¹⁾, at 24.8% of sales, is € 174.0 million, an increase of 15.4% over the same period of the preceding year. 

• Operating income, at 21.1% of sales, is € 148.3 million, an increase of 12.0% over the same period of the preceding year. Included is an € 8.0 million provision covering the completion of the sales force reorganization in the French subsidiary. 

• Net income, at 14.5% of sales is € 101.5 million, an increase of 9.0% over the first nine months 2012. 

• Net financial position⁽²⁾ at 30 September 2013 records a net debt of € 133.3 million. During the period $ 100.0 million (€ 75.0 million) were paid for the acquisition of a portfolio of products for the treatment of rare and other diseases, sold mainly in the U.S.A., from Lundbeck LLC, and dividends were distributed for a total of € 20.1 million. Shareholders' equity increases to € 722.0 million. 

⁽¹⁾ Earnings before interest, taxes, depreciation and amortization.
⁽²⁾ Cash and short-term financial investments less bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge).